LORLATINIB

Information current as at: 1 June 2026

PBAC meeting date: July 2021
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Lorviqua®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
Pfizer Australia Pty Ltd
Condition/indication:
(therapeutic use)
  • Locally advanced (stage IIIB) or metastatic (stage IV) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
Change to listing (Category 1-2)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
July 2021 PBAC meeting
Opportunity for consumer comment:
Open 21/03/2021 and close 26/05/2021 (see PBS Website)
PBAC meeting:
Held on 07/07/2021
PBAC outcome published:
Deferred (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – July 2021
Case ID
a358
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19